Statistici de bază
| LEI | 5493005QORQTZCZYOP39 |
| CIK | 1422143 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Kura Oncology, Inc.
SEC Filings (Chronological Order)
Această pagină oferă o listă completă, cronologică, a dosarelor SEC, cu excepția dosarelor de proprietate pe care le oferim în altă parte.
| June 4, 2026 |
As filed with the Securities and Exchange Commission on June 4, 2026 As filed with the Securities and Exchange Commission on June 4, 2026 Registration No. |
|
| June 4, 2026 |
Exhibit 99.1 Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan Amended and Restated by the Board: March 6, 2015 Approved by the Stockholders: March 6, 2015 Amended by the Board: September 26, 2022 and April 4, 2023 Approved by the Stockholders: May 31, 2023 Amended by the Board: April 7, 2024 Approved by the Stockholders: June 5, 2024 Amended by the Board: April 8, 2025 Approved |
|
| June 4, 2026 |
Calculation of Filing Fee Tables Form S-8 Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Kura Oncology, Inc. |
|
| June 4, 2026 |
Exhibit 99.2 Kura Oncology, Inc. Amended and Restated 2015 Employee Stock Purchase Plan ADOPTED BY THE BOARD OF DIRECTORS: MARCH 6, 2015 APPROVED BY THE STOCKHOLDERS: MARCH 6, 2015 Amended by the Board of Directors: April 9, 2026 Approved by the Stockholders: June 4, 2026 1. General; Purpose. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Co |
|
| June 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2026 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 26, 2026 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| May 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37620 KURA ONCO |
|
| May 12, 2026 |
Exhibit 99.1 Kura Oncology Reports FIRST Quarter 2026 Financial Results – $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching and combination adoption, reflect strong early momentum – – Broad and rapid payer access achieved, with > 93% coverage and favorable po |
|
| May 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2026 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| April 10, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Defini |
|
| April 10, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37620 KURA ONCOLOGY, |
|
| April 10, 2026 |
x UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| March 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37620 KURA ONCOLOGY, |
|
| March 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2026 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 5, 2026 |
Exhibit 99.1 Kura Oncology Reports Fourth Quarter and full year 2025 Financial Results – KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions – – Market feedback emphasizes differentiated safety, combinability and convenience of ziftomenib, supporting ongoing development plans targeting up to 50% of AML patients – – Orange Book listing of patents exten |
|
| March 5, 2026 |
Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.11 Amended and Restated Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Kura Oncology, Inc. (“Kura”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Amended and Restated Non-Employee Director Compensation Policy (this “Policy”) for |
|
| January 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2026 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| January 29, 2026 |
EX-99.1 Exhibit 99.1 AMENDED AND RESTATED BYLAWS OF KURA ONCOLOGY, INC. (A DELAWARE CORPORATION) AMENDED AND RESTATED EFFECTIVE AS OF JANUARY 28, 2026 ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware and the name of the corporation’s registered agent at such address shall be as set forth in the certificate of incorporation of the cor |
|
| January 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2026 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| January 12, 2026 |
EX-99.1 Exhibit 99.1 Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones – Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML – – $2.1 million KOMZIFTI net product revenue for the period from first commercial sale on November 21, 2025, through December 31, 2025 – – |
|
| December 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2025 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2025 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 4, 2025 |
As filed with the Securities and Exchange Commission on November 4, 2025 S-8 As filed with the Securities and Exchange Commission on November 4, 2025 Registration No. |
|
| November 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37620 KURA |
|
| November 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 4, 2025 |
SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT Exhibit 10.2 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of October 25, 2025 (the “Amendment Effective Date”), is entered into by and between Kura Oncology, Inc., a Delaware corporation, together with any Subsidiaries from time to time party to the Loan Agreement (collectively referred to as “Borrower”), the seve |
|
| November 4, 2025 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Kura Oncology, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.0001 par value per share, Kura Oncology, Inc. 2023 Inducement Option Plan, as amended Other 750, |
|
| November 4, 2025 |
Exhibit 99.1 Kura Oncology Reports Third Quarter 2025 Financial Results – KOMET 017 Phase 3 trials to evaluate ziftomenib in combination with intensive and non-intensive chemotherapy in frontline AML are accelerating; ziftomenib being investigated in settings representing more than 50% of AML patients – – Two oral presentations at 2025 ASH Annual Meeting on ziftomenib in combination with venetocla |
|
| October 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2025 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| October 16, 2025 |
EX-99.1 Exhibit 99.1 KURA ONCOLOGY, INC. 2023 INDUCEMENT OPTION PLAN ADOPTED BY THE BOARD OF DIRECTORS: DECEMBER 18, 2023 AMENDED BY THE BOARD OF DIRECTORS: DECEMBER 16, 2024 AMENDED BY THE BOARD OF DIRECTORS: OCTOBER 15, 2025 1. GENERAL. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement gra |
|
| October 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2025 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| September 29, 2025 |
144 0001934232 XXXXXXXX LIVE 0001422143 KURA ONCOLOGY, INC. 001-37620 12730 High Bluff Drive San Diego CA 92130 (858)-500-8800 POWL BRIAN T Officer Common Stock Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 8891 80463.55 87015518 09/29/2025 NASDAQ Common Stock 09/27/2025 RSU Issuer N 8891 09/29/2025 N/A Y 09/29/2025 Thomas Doyle, Attorney |
|
| September 29, 2025 |
144 0001589597 XXXXXXXX LIVE 0001422143 KURA ONCOLOGY, INC. 001-37620 12730 High Bluff Drive San Diego CA 92130 (858)-500-8800 WILSON TROY EDWARD Officer Director Common Stock Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 36615 331365.75 87015518 09/29/2025 NASDAQ Common Stock 09/27/2025 PSU Issuer N 36615 09/29/2025 N/A Y 09/29/2025 Thom |
|
| September 29, 2025 |
144 0001910331 XXXXXXXX LIVE 0001422143 KURA ONCOLOGY, INC. 001-37620 12730 High Bluff Drive San Diego CA 92130 (858)-500-8800 DOYLE THOMAS JAMES Officer Common Stock Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 4541 41096.05 87015518 09/29/2025 NASDAQ Common Stock 09/27/2025 PSU Issuer N 4541 09/29/2025 N/A Y 09/29/2025 /s/ Thomas Doyle |
|
| September 29, 2025 |
144 0001785406 XXXXXXXX LIVE 0001422143 KURA ONCOLOGY, INC. 001-37620 12730 High Bluff Drive San Diego CA 92130 (858)-500-8800 FORD KATHLEEN Officer Common Stock Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 6892 62372.6 87015518 09/29/2025 NASDAQ Common Stock 09/27/2025 PSU Issuer N 6892 09/29/2025 N/A Y 09/29/2025 Thomas Doyle, Attorney |
|
| September 29, 2025 |
144 0001813058 XXXXXXXX LIVE 0001422143 KURA ONCOLOGY, INC. 001-37620 12730 High Bluff Drive San Diego CA 92130 (858)-500-8800 BAIR TERESA BROPHY Officer Common Stock Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 8805 79685.25 87015518 09/29/2025 NASDAQ Common Stock 09/27/2025 PSU Issuer N 8805 09/29/2025 N/A Y 09/29/2025 Thomas Doyle, At |
|
| September 29, 2025 |
144 0002051106 XXXXXXXX LIVE 0001422143 KURA ONCOLOGY, INC. 001-37620 12730 High Bluff Drive San Diego CA 92130 (858)-500-8800 LEONI MOLLIE Officer Common Stock Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 12314 111441.7 87015518 09/29/2025 NASDAQ Common Stock 09/27/2025 PSU Issuer N 12314 09/29/2025 N/A Y 09/29/2025 Thomas Doyle, Attorn |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 7, 2025 |
Exhibit 10.2 First Amendment TO lease This first Amendment to lease (this "First Amendment") is made and entered into effective as of June 6, 2025 (the "Effective Date") by and between HCP LIFE SCIENCE REIT, INC., a Maryland corporation ("Landlord") and KURA ONCOLOGY, INC., a Delaware corporation ("Tenant"). R E C I T A L S A. Landlord is the owner of that certain building located at 4930 Director |
|
| August 7, 2025 |
Exhibit 10.1 FIRST AMENDMENT TO LEASE This FIRST AMENDMENT TO LEASE (“First Amendment”) is made and entered into effective as of May 6, 2025, by and between BP3-SD5 5510 MOREHOUSE DRIVE LLC, a Delaware limited liability company (“Landlord”) and KURA ONCOLOGY, INC., a Delaware corporation (“Tenant”). r e c i t a l s : A. Landlord and Tenant entered into that certain Lease dated as of May 11, 2021 ( |
|
| August 7, 2025 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT KURA ONCOLOGY, INC. |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37620 KURA ONCOL |
|
| August 7, 2025 |
Exhibit 99.1 Kura Oncology Reports Second Quarter 2025 Financial Results – FDA Priority Review of New Drug Application (NDA) for ziftomenib in adults with R/R NPM1-m AML with Prescription Drug User Fee Act (PDUFA) target action date set for November 30, 2025 – – Fully engaged in commercial readiness activities in alignment with regulatory review timeline – – KOMET-017-IC (intensive chemotherapy) a |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 Kura Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37620 61-1547851 (State or other jurisdiction of incorporation) (Commission File |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 18, 2025 |
June 18, 2025 2025 EHA ANALYST AND INVESTOR EVENT Our goal is to develop transformative therapies to extend and improve the lives of patients with cancer Exhibit 99. |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| June 6, 2025 |
As filed with the Securities and Exchange Commission on June 6, 2025 As filed with the Securities and Exchange Commission on June 6, 2025 Registration No. |
|
| June 6, 2025 |
Exhibit 99.1 Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan Amended and Restated by the Board: March 6, 2015 Approved by the Stockholders: March 6, 2015 Amended by the Board: September 26, 2022 and April 4, 2023 Approved by the Stockholders: May 31, 2023 Amended by the Board: April 7, 2024 Approved by the Stockholders: June 5, 2024 Amended by the Board: April 8, 2025 Approved |
|
| June 6, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Kura Oncology, Inc. |
|
| June 3, 2025 |
June 2, 2025 2025 ASCO ANALYST AND INVESTOR EVENT Our goal is to develop transformative therapies to extend and improve the lives of patients with cancer Exhibit 99. |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2025 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37620 KURA ONCO |
|
| May 1, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2025 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 1, 2025 |
Exhibit 99.1 Kura Oncology Reports First Quarter 2025 Financial Results – NDA submitted in 1Q 2025 for ziftomenib for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation – – Data from Phase 1b/2 registration-directed trial of ziftomenib selected for oral presentation at ASCO Annual Meeting – – $45.0 million milestone payment earned for NDA submission under collabo |
|
| April 17, 2025 |
2024 ANNUAL REPORT KURA ONCOLOGY 2024 ANNUAL REPORTKura is dedicated to helping patients with cancer lead better, longer lives through the discovery and development of targeted small molecule drug candidates for disease indications of unmet medical need. |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Defini |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini |
|
| February 28, 2025 |
Exhibit 10.33 WITHOUT PREJUDICE AND SUBJECT TO CONTRACT SETTLEMENT AGREEMENT THIS AGREEMENT is made on January 1, 2025 BETWEEN: (1) KURA ONCOLOGY, INC. (the "Company"); and (2) STEPHEN DALE (the "Executive"). BACKGROUND: (A) The Executive is employed by the Company on the terms of their Employment Agreement as Chief Medical Officer. (B) The Executive wishes to resign from his employment with the C |
|
| February 28, 2025 |
As filed with the Securities and Exchange Commission on February 28, 2025 As filed with the Securities and Exchange Commission on February 28, 2025 Registration No. |
|
| February 28, 2025 |
Exhibit 10.35 Kura Oncology, Inc. third Amended & Restated Executive Employment Agreement for FRANCIS BURROWS This Third Amended & Restated Executive Employment Agreement (the “Agreement”), entered into between Kura Oncology, Inc. (the “Company”) and FRANCIS BURROWS (the “Executive”) (collectively, the “Parties”), is effective as of January 2, 2025. Whereas, Executive has been employed by the Comp |
|
| February 28, 2025 |
Kura Oncology, Inc. Insider Trading Policy Exhibit 19.1 I. Introduction This Insider Trading Policy of Kura Oncology, Inc. (the “Company”) applies to all directors, officers, other employees, consultants and certain designated contractors of the Company and any subsidiaries. It also applies to their family members who reside with them, anyone else who lives in their households and any family members who do not live in their households but |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37620 KURA ONCOLOGY, |
|
| February 28, 2025 |
Exhibit 10.32 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT KURA ONCOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL CONFIDENTIAL Execution Version Collaboration and license AGREEMENT This Collaboration and License Agreement (this “Agreement”) is made as of November 20, 2024 (the “Effective |
|
| February 28, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Kura Oncology, Inc. |
|
| February 28, 2025 |
Amended and Restated Non-Employee Director Compensation Policy. Exhibit 10.15 Amended and Restated Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Kura Oncology, Inc. (“Kura”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Amended and Restated Non-Employee Director Compensation Policy (this “Policy”) for |
|
| February 28, 2025 |
Exhibit 10.34 Kura Oncology, Inc. Third Amended & Restated Executive Employment Agreement for MOLLIE LEONI This Third Amended & Restated Executive Employment Agreement (the “Agreement”), entered into between Kura Oncology, Inc. (the “Company”) and MOLLIE LEONI (the “Executive”) (collectively, the “Parties”), is effective as of January 2, 2025. Whereas, Executive has been employed by the Company as |
|
| February 28, 2025 |
Lease, effective January 13, 2025, by and between the Registrant and HCP Life Science REIT, Inc. Exhibit 10.36 DIRECTORS SCIENCE PARK LEASE This Lease (the "Lease"), dated as of the Effective Date set forth in Section 1 of the Summary of Basic Lease Information below (the "Summary"), is made by and between HCP LIFE SCIENCE REIT, INC., a Maryland corporation ("Landlord"), and KURA ONCOLOGY, INC., a Delaware corporation ("Tenant"). The Tenant originally named in the foregoing sentence may be re |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 26, 2025 |
Exhibit 99.1 Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results – KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint – – Alignment reached with FDA and EMA on key aspects of the KOMET-017 protocol including use of MRD-negative CR endpoint for potential U.S. accelerated approval pathway in frontline intensive chemotherapy trial – – Topline MRD-neg |
|
| February 13, 2025 |
Exhibit A JOINT FILING AGREEMENT The undersigned agree that this Schedule 13G Amendment No. |
|
| February 13, 2025 |
Exhibit B CONTROL PERSON IDENTIFICATION Suvretta Capital Management, LLC is the relevant entity for which Aaron Cowen is the control person. |
|
| February 13, 2025 |
EX-99.A 2 e664194ex99-a.htm Exhibit A Joint Filing Agreement The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of Kura Oncology, Inc. shall be filed on behalf of the undersigned. DEERFIELD MGMT, L.P. By: J.E. Flynn Capital, LLC, General Partner By: /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact DEERFIELD MANAGEMENT COMPANY, L.P. By: Flynn M |
|
| February 13, 2025 |
EX-99.B 3 e664194ex99-b.htm Exhibit B Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a “group” with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934. |
|
| February 5, 2025 |
February 5, 2025 ZIFTOMENIB PROGRAM UPDATES Our goal is to develop transformative therapies to extend and improve the lives of patients with cancer Exhibit 99. |
|
| February 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2025 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 4, 2025 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated February 4, 2025 with respect to the Common Stock, $0.0001 par value per share, of Kura Oncology, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| January 8, 2025 |
KURA / Kura Oncology, Inc. / BlackRock, Inc. - POWER OF ATTORNEY begin 644 POA.pdf M)5!$1BTQ+C<*"C0@,"!O8FH**$ED96YT:71Y*0IE;F1O8FH*-2 P(&]B:@HH M061O8F4I"F5N9&]B:@HX(# @;V)J"CP\"B]&:6QT97(@+T9L871E1&5C;V1E M"B],96YG=&@@,3@P-3,*+TQE;F=T:#$@-#4V-38*+U1Y<&4@+U-T]QPZ1L=H1AI)(XUF-#I&TNB6K,.2/-9M M6Y)EV98E&]N29?G"%[;!-HW75U\TT&B0QEX6]^Z>%X'4A2>N1UI5$?OPL5'YAV<@^<]*,[I6+RT MN;VEZC&B>VXCLNQ;N+BT8N2F?08TN0UAT:V#&^ON7[6$:+H9XG4>T?.V>7V M9]&/B3(:4+YGW?;U6]:4C%] % ?X\9;UP |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2025 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| December 20, 2024 |
Exhibit 99.1 KURA ONCOLOGY, INC. 2023 INDUCEMENT OPTION PLAN ADOPTED BY THE BOARD OF DIRECTORS: DECEMBER 18, 2023 AMENDED BY THE BOARD OF DIRECTORS: DECEMBER 16, 2024 1. GENERAL. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| December 5, 2024 |
EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of December 5, 2024 is by and among RA Capital Management, L. |
|
| December 5, 2024 |
KURA / Kura Oncology, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment SC 13G 1 tm2430332d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Kura Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 50127T109 (CUSIP Number) November 27, 2024 (Date of Event Which Requires Filing of this Statement) Check the |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 Kura Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37620 61-1547851 (State or other jurisdiction of incorporation) (Commission F |
|
| November 14, 2024 |
KURA / Kura Oncology, Inc. / Paradigm Biocapital Advisors LP - SC 13G/A Passive Investment SC 13G/A 1 tm2427604d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kura Oncology, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 50127T109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this statement) Ch |
|
| November 14, 2024 |
SC 13G/A 1 sc13ga307422kura11142024.htm AMENDMENT NO. 3 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 Kura Oncology, Inc. (Name of Issuer) Common Stock, par value $0.00 |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 7, 2024 |
Exhibit 99.1 Kura Oncology Reports Third Quarter 2024 Financial Results – Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The Lancet Oncology – – Data from 100 patients in Phase 1a dose-escalation study of ziftomenib combined with ven/aza in R/R AML and 7+3 in 1L adverse risk AML to be presented at ASH – – P |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37620 KURA |
|
| September 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2024 Kura Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37620 61-1547851 (State or other jurisdiction of incorporation) (Commission |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37620 KURA ONCOL |
|
| August 8, 2024 |
Exhibit 10.1 Kura Oncology, Inc. Second Amendment to Amended and Restated Executive Employment Agreement This Second Amendment to Amended and Restated Executive Employment Agreement (this “Amendment”), amending that certain Amended and Restated Executive Employment Agreement effective as of January 29, 2016, as amended by that certain Amendment to Amended and Restated Executive Employment Agreemen |
|
| August 8, 2024 |
Exhibit 99.1 Kura Oncology Reports Second Quarter 2024 Financial Results – Topline data from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025 – – Breakthrough Therapy Designation granted for ziftomenib in R/R NPM1-mutant AML – – Data from 100 patients in KOMET-007 trial of ziftomenib in combination with ven/aza and 7+3 expected in Q4; Phase 1b expansion study |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 7, 2024 |
Exhibit 99.1 Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan Amended and Restated by the Board: March 6, 2015 Approved by the Stockholders: March 6, 2015 Amended by the Board: September 26, 2022 and April 4, 2023 Approved by the Stockholders: May 31, 2023 Amended by the Board: April 7, 2024 Approved by the Stockholders: June 5, 2024 1. General. (a) Eligible Award Recipients. Em |
|
| June 7, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Kura Oncology, Inc. |
|
| June 7, 2024 |
As filed with the Securities and Exchange Commission on June 7, 2024 As filed with the Securities and Exchange Commission on June 7, 2024 Registration No. |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 2, 2024 |
EX-99.1 2 tm2412729d1ex-1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0.0001 par value per share, of Kura Oncology, Inc., and further ag |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37620 KURA ONCO |
|
| May 2, 2024 |
KURA / Kura Oncology, Inc. / Paradigm Biocapital Advisors LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Kura Oncology, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 50127T109 (CUSIP Number) April 22, 2024 (Date of Event Which Requires Filing of this statement) Check the appropriate box to designate the rule p |
|
| May 2, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 2, 2024 |
Exhibit 99.1 Kura Oncology Reports First Quarter 2024 Financial Results – Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – – Positive preliminary combination data for ziftomenib in NPM1-mutant and KMT2A-rearranged AML – – First patient dosed with KO-2806 and cabozantinib |
|
| April 18, 2024 |
2023 ANNUAL REPORT REALIZING THE PROMISEZiftomenib Demonstrates Potential to Become a Cornerstone of AML Therapy • Good tolerability profile enabling continuous administration in combination with standards of care • No observed or predicted drug-drug interactions • Combinations appear to mitigate the risk of differentiation syndrome • Encouraging preliminary evidence of clinical activity as a comb |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Defini |
|
| February 29, 2024 |
United States securities and exchange commission logo February 12, 2024 Troy Wilson, Ph. |
|
| February 27, 2024 |
As filed with the Securities and Exchange Commission on February 27, 2024 As filed with the Securities and Exchange Commission on February 27, 2024 Registration No. |
|
| February 27, 2024 |
Kura Oncology, Inc. Incentive Compensation Recoupment Policy. Exhibit 97.1 Kura Oncology, Inc. Incentive Compensation Recoupment Policy 1. Introduction The Board of Directors (the “Board”) of Kura Oncology, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment of Recoverable |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37620 KURA ONCOLOGY, |
|
| February 27, 2024 |
Exhibit 99.1 Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results – Positive preliminary combination data from KOMET-007 trial of ziftomenib in NPM1-m and KMT2A-r AML, including effective mitigation of differentiation syndrome – – First patient dosed in KOMET-008 trial of ziftomenib in combination with additional standards of care, including gilteritinib, FLAG-IDA and LDAC, in |
|
| February 27, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Kura Oncology, Inc. |
|
| February 27, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 15, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-276995 PROSPECTUS 8,695,699 Shares Common Stock This prospectus relates to the offer and resale from time to time of up to an aggregate of 8,695,699 shares of our common stock, par value $0.0001 per share (the “Resale Shares”), of which 1,376,813 shares are issued and outstanding and 7,318,886 shares (the “Warrant Shares”) are |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Kura Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 50127T109 (CUSIP Number) Dec |
|
| February 14, 2024 |
Kura Oncology, Inc. 12730 High Bluff Drive Suite 400 San Diego, CA 92130 (858) 500-8800 Kura Oncology, Inc. 12730 High Bluff Drive Suite 400 San Diego, CA 92130 (858) 500-8800 February 14, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford Re: Kura Oncology, Inc. Registration Statement on Form S-3 File No. 333-276995 Ladies and Gentlemen: Kura Oncology, Inc. (the “Registrant”) |
|
| February 14, 2024 |
KURA / Kura Oncology, Inc. / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Kura Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 50127T109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 13, 2024 |
KURA / Kura Oncology, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01303-kuraoncologyinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Kura Oncology Inc Title of Class of Securities: Common Stock CUSIP Number: 50127T109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate |
|
| February 13, 2024 |
KURA / Kura Oncology, Inc. / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment SC 13G/A 1 d1096419313g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Kura Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 50127T109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| February 13, 2024 |
Kura Oncology, Inc. 12730 High Bluff Drive Suite 400 San Diego, CA 92130 (858) 500-8800 Kura Oncology, Inc. 12730 High Bluff Drive Suite 400 San Diego, CA 92130 (858) 500-8800 February 13, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford Re: Kura Oncology, Inc. Registration Statement on Form S-3 File No. 333-276995 Ladies and Gentlemen: Kura Oncology, Inc. (the “Registrant”) |
|
| February 12, 2024 |
KURA / Kura Oncology, Inc. / Flynn James E Passive Investment SC 13G/A 1 e619259sc13ga-kura.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) * Kura Oncology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 50127T109 (CUSIP Number) December 31, 20 |
|
| February 9, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Kura Oncology, Inc. |
|
| February 9, 2024 |
As filed with the Securities and Exchange Commission on February 9, 2024 Table of Contents As filed with the Securities and Exchange Commission on February 9, 2024 Registration No. |
|
| January 30, 2024 |
Exhibit 99.1 DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER Preliminary Data from KOMET-007 – January 30, 2024 WELCOME AND INTRODUCTION Troy Wilson, Ph.D., J.D. – President & Chief Executive Officer, Kura Oncology Forward-Looking Statements This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclini |
|
| January 30, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| January 26, 2024 |
EX-4.1 Exhibit 4.1 THE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. THE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES REPRESENTED HEREBY MAY NOT BE OFFERED |
|
| January 26, 2024 |
EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of January 26, 2024, by and among Kura Oncology, Inc., a Delaware corporation (the “Company”), and the purchasers set forth on Schedule 1 hereto (each, a “Purchaser”, and collectively, the “Purchasers”), and shall become effective as of the Closing (as defined in the Purchase Agreemen |
|
| January 26, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of January 24, 2024, by and among Kura Oncology, Inc., a Delaware corporation (the “Company”), and each purchaser identified on Schedule 1 hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. On the terms and subject to the conditio |
|
| January 26, 2024 |
Exhibit 99.1 Kura Oncology Announces Oversubscribed $150 Million Private Placement – Funding from existing investors, including EcoR1 Capital, an affiliate of Deerfield Management and Suvretta Capital – – Pro forma cash, cash equivalents and investments expected to provide runway into 2027 – – Management to host virtual investor event at 8:00 a.m. ET on January 30 to highlight preliminary combinat |
|
| January 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2024 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| January 24, 2024 |
KURA / Kura Oncology, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us50127t1097012424.txt us50127t1097012424.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 5) Kura Oncology Inc - (Name of Issuer) Common Stock - (Title of Class of Securities) 50127T109 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| January 23, 2024 |
KURA / Kura Oncology, Inc. / STATE STREET CORP Passive Investment SC 13G/A 1 KuraOncologyInc.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXIT FILING KURA ONCOLOGY INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 50127T109 (CUSIP NUMBER) 12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO |
|
| December 22, 2023 |
KURA ONCOLOGY, INC. 2023 INDUCEMENT OPTION PLAN ADOPTED BY THE BOARD OF DIRECTORS: DECEMBER 18, 2023 EX-99.1 Exhibit 99.1 KURA ONCOLOGY, INC. 2023 INDUCEMENT OPTION PLAN ADOPTED BY THE BOARD OF DIRECTORS: DECEMBER 18, 2023 1. GENERAL. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 2, 2023 |
Exhibit 99.1 Kura Oncology Reports Third Quarter 2023 Financial Results – Completion of enrollment in KOMET-001 registration-directed trial of ziftomenib in NPM1-mutant AML expected by mid-2024 – – Preliminary data from 20 patients in KOMET-007 combination trial of ziftomenib anticipated early in first quarter of 2024 – – First patient dosed in FIT-001 dose-escalation study of next-generation FTI, |
|
| November 2, 2023 |
Exhibit 10.4 KURA ONCOLOGY, INC. $150,000,000 COMMON STOCK SALES AGREEMENT November 2, 2023 Leerink Partners LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Cantor Fitzgerald & Co. 110 E. 59th Street New York, NY 10022 Ladies and Gentlemen: Kura Oncology, Inc., a Delaware corporation (the “Company”), Leerink Partners LLC (“Leerink Partners”), as lead sales agent, and Cantor Fi |
|
| November 2, 2023 |
Exhibit 10.1 Executive Employment Agreement for Brian Powl This Executive Employment Agreement (the “Agreement”), entered into between Kura Oncology, Inc. (the “Company”) and Brian Powl (the “Executive”) (collectively, the “Parties”), is effective as of August 14, 2023 (the “Effective Date”). Whereas, the Company desires Executive to provide employment services to the Company, and wishes to provid |
|
| November 2, 2023 |
Exhibit 10.2 First Amendment to Lease This First Amendment to Lease (this “Amendment”), is made as of the 30th day of August, 2023, by and between EAST OFFICE OPERATING LIMITED PARTNERSHIP, a Massachusetts limited partnership, with an address c/o Pembroke Real Estate LLC, 255 State Street, Boston, Massachusetts 02109 (the “Landlord”) and KURA ONCOLOGY, INC, a Delaware corporation, with an address |
|
| November 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 2, 2023 |
Form of Indenture, between the Registrant and one or more trustees to be named. EXHIBIT 4.8 KURA ONCOLOGY, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Section |
|
| November 2, 2023 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. EXHIBIT 4.13 KURA ONCOLOGY, INC. and , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF [ ], 20 KURA ONCOLOGY, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of between KURA ONCOLOGY, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existi |
|
| November 2, 2023 |
Exhibit 10.3 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of October 2, 2023 (the “Amendment Effective Date”), is entered into by and between Kura Oncology, Inc., a Delaware corporation, together with any Subsidiaries from time to time party to the Loan Agreement (collectively referred to as “Borrower”), the several |
|
| November 2, 2023 |
Form of Common Stock Warrant Agreement and Warrant Certificate. EXHIBIT 4.11 KURA ONCOLOGY, INC. and , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF [ ], 20 KURA ONCOLOGY, INC. FORM OF COMMON STOCK WARRANT AGREEMENT COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between KURA ONCOLOGY, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under th |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37620 KURA |
|
| November 2, 2023 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. EXHIBIT 4.12 KURA ONCOLOGY, INC. and , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF [ ], 20 KURA ONCOLOGY, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between KURA ONCOLOGY, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and exist |
|
| November 2, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Kura Oncology, Inc. |
|
| November 2, 2023 |
As filed with the Securities and Exchange Commission on November 2, 2023 Table of Contents As filed with the Securities and Exchange Commission on November 2, 2023 Registration No. |
|
| September 21, 2023 |
KURA / Kura Oncology Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2023 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37620 KURA ONCOL |
|
| August 9, 2023 |
Exhibit 10.2 Stock Option Grant Notice - International (Amended and Restated 2014 Equity Incentive Plan) Kura Oncology, Inc. (the “Company”), pursuant to its Amended and Restated 2014 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as |
|
| August 9, 2023 |
Amended and Restated Non-Employee Director Compensation Policy. Exhibit 10.1 Amended and Restated Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Kura Oncology, Inc. (“Kura”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Amended and Restated Non-Employee Director Compensation Policy (this “Policy”) for |
|
| August 3, 2023 |
Exhibit 99.1 Kura Oncology Reports Second Quarter 2023 Financial Results – Enrollment in registration-directed trial of ziftomenib in NPM1-mutant AML continues to outperform projections – – First patients dosed in combination study of ziftomenib in NPM1-mutant and KMT2A-rearranged AML – – Late-breaking clinical data for ziftomenib in NPM1-mutant AML presented at EHA – – Continued evidence of clini |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 14, 2023 |
EX-99.2 Exhibit 99.2 Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants SAN DIEGO, June 14, 2023 – Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of common stock and |
|
| June 14, 2023 |
Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants EX-99.1 Exhibit 99.1 Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants SAN DIEGO, June 13, 2023 – Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has commenced an underwritten public offering, subject to market a |
|
| June 14, 2023 |
EX-4.1 Exhibit 4.1 KURA ONCOLOGY, INC. [FORM OF] WARRANT TO PURCHASE SHARES OF COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. CS—[ ] Original Issue Date: June [ ], 2023 Kura Oncology, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered as |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 14, 2023 |
EX-1.1 Exhibit 1.1 Execution Version KURA ONCOLOGY, INC. (a Delaware corporation) 5,660,871 Shares of Common Stock Pre-Funded Warrants to Purchase 3,034,782 Shares of Common Stock UNDERWRITING AGREEMENT Dated: June 13, 2023 KURA ONCOLOGY, INC. (a Delaware corporation) 5,660,871 Shares of Common Stock Pre-Funded Warrants to Purchase 3,034,782 Shares of Common Stock UNDERWRITING AGREEMENT June 13, 2 |
|
| June 14, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Kura Oncology, Inc. |
|
| June 14, 2023 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-251172 PROSPECTUS SUPPLEMENT (To Prospectus dated December 7, 2020) 5,660,871 Shares of Common Stock Pre-Funded Warrants to Purchase up to 3,034,782 Shares of Common Stock We are offering 5,660,871 shares of our common stock and, in lieu of offering shares of our common stock to certain investors, pre-funded warrants to |
|
| June 13, 2023 |
SUBJECT TO COMPLETION, DATED JUNE 13, 2023 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-251172 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has become effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we are not soliciting offers to b |
|
| June 12, 2023 |
EX-99.1 EHA Investor Event – June 12, 2023 DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER Exhibit 99.1 This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected timelines for ziftomenib, tipifarnib and KO-2806, plans regarding regulatory |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2023 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 2, 2023 |
Exhibit 99.1 Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan Amended and Restated by the Board: March 6, 2015 Approved by the Stockholders: March 6, 2015 Amended by the Board: September 26, 2022 and April 4, 2023 Approved by the Stockholders: May 31, 2023 1. General. (a) Eligible Award Recipients. Employees, Directors and Consultants are eligible to receive Awards. (b) Availabl |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| June 2, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Kura Oncology, Inc. |
|
| June 2, 2023 |
As filed with the Securities and Exchange Commission on June 2, 2023 As filed with the Securities and Exchange Commission on June 2, 2023 Registration No. |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37620 KURA ONCO |
|
| May 10, 2023 |
Exhibit 99.1 Kura Oncology Reports First Quarter 2023 Financial Results – Evolving data from Phase 1 trial of ziftomenib in NPM1-mutant AML to be presented at EHA – – Site activation and enrollment in Phase 2 registration-directed trial of ziftomenib in NPM1-mutant AML outperforming projections – – First combination study of ziftomenib in NPM1-mutant and KMT2A-rearranged AML to dose first patients |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 10, 2023 |
Exhibit 10.1 Kura Oncology, Inc. January 11, 2023 Kirsten Flowers 31 Cherry Hills Farm Drive Englewood, CO 80113 Re: Transition And Separation Agreement Dear Kirsten: Kura Oncology, Inc. (the “Company”) has accepted your notice of resignation to pursue other opportunities. This letter sets forth the terms of the separation agreement (the “Agreement”) that the Company is offering to you to aid in y |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| April 20, 2023 |
ANNUAL REPORT 2 2 22 22 OPTIMIZING OUR POTENTIALThe portrait on the cover is a representation of an actual patient enrolled in clinical studies (see page 4 for clinical patient profiles). |
|
| April 19, 2023 |
EX-99.1 Exhibit 99.1 Background: The menin and histone-lysine-N-methyltransferase 2A (KMT2A) protein complex is an essential epigenetic regulator of genes critical for maintenance of multiple genetic subtypes of leukemia. This complex is implicated in NPM1 mutant acute myeloid leukemia (AML) (NPM1m, 25-30% of AML) as well as AML with KMT2A gene rearrangements (KMT2Ar; 5-10% of AMLs). The presence |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2023 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 6, 2023 |
DEFA14A 1 kuradefa14a2023.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as p |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 24, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Kura Oncology, Inc. |
|
| February 24, 2023 |
As filed with the Securities and Exchange Commission on February 23, 2023 As filed with the Securities and Exchange Commission on February 23, 2023 Registration No. |
|
| February 23, 2023 |
Exhibit 4.4 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNS |
|
| February 23, 2023 |
Form of Warrant Agreement issued by the Registrant on November 2, 2022 to certain Lenders. Exhibit 4.3 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNS |
|
| February 23, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 23, 2023 |
Exhibit 99.1 Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results – Phase 1 data for ziftomenib highlighted by 30% CR rate among 20 patients with NPM1-mutant AML treated at recommended Phase 2 dose – – Multiple patients dosed in registration-directed trial of ziftomenib in NPM1-mutant AML – – First combination study of ziftomenib in NPM1-mutant and KMT2A-rearranged AML on trac |
|
| February 23, 2023 |
Exhibit 10.22 Kura Oncology, Inc. RSU Award Grant Notice (Amended and Restated 2014 Equity Incentive Plan) Kura Oncology, Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the “RSU Award”). Your RSU Award is subject to all of the terms and conditions as set forth herein and |
|
| February 23, 2023 |
Exhibit 10.1 KURA ONCOLOGY, INC. AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN AMENDED AND RESTATED BY THE BOARD: MARCH 6, 2015 APPROVED BY THE STOCKHOLDERS: MARCH 6, 2015 1. GENERAL. (a) Eligible Award Recipients. Employees, Directors and Consultants are eligible to receive Awards. (b) Available Awards. The Plan provides for the grant of the following Awards: (i) Incentive Stock Options, (ii) N |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37620 KURA ONCOLOGY, |
|
| February 23, 2023 |
Exhibit 4.5 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNS |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION February 21, 2023 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 Kura Oncology, Inc. |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Kura Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 50127T109 (CUSIP Number) Dec |
|
| February 14, 2023 |
KURA / Kura Oncology Inc / Avoro Capital Advisors LLC - KURA ONCOLOGY, INC. Passive Investment SC 13G/A 1 p23-0586sc13ga.htm KURA ONCOLOGY, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kura Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 50127T109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check t |
|
| February 14, 2023 |
KURA / Kura Oncology Inc / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-kura123122a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kura Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 50127T109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check t |
|
| February 13, 2023 |
KURA / Kura Oncology Inc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment SC 13G/A 1 d992732113g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Kura Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 50127T109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| February 10, 2023 |
KURA / Kura Oncology Inc / Flynn James E Passive Investment SC 13G/A 1 e618248sc13ga-ko.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) * Kura Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 50127T109 (CU |
|
| February 10, 2023 |
KURA / Kura Oncology Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Kura Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 50127T109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 9, 2023 |
KURA / Kura Oncology Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv01263-kuraoncologyinc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Kura Oncology Inc. Title of Class of Securities: Common Stock CUSIP Number: 50127T109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to wh |
|
| February 3, 2023 |
KURA / Kura Oncology Inc / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 AMENDED FILING KURA ONCOLOGY INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 50127T109 (CUSIP NUMBER) 12/31/2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILE |
|
| January 31, 2023 |
KURA / Kura Oncology Inc / BlackRock Inc. Passive Investment us50127t1097013123.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 4) Kura Oncology Inc - (Name of Issuer) Common Stock - (Title of Class of Securities) 50127T109 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| January 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| January 9, 2023 |
DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER Corporate Presentation – January 2023 Exhibit 99. |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2022 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| December 5, 2022 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated December 5, 2022 with respect to the Common Stock, par value $0.0001 per share, of Kura Oncology, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with |
|
| December 5, 2022 |
KURA / Kura Oncology Inc / BIOTECHNOLOGY VALUE FUND L P - THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Kura Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 50127T109 (CUSIP Number) Nove |
|
| November 3, 2022 |
Exhibit 99.1 Kura Oncology Reports Third Quarter 2022 Financial Results – Abstract reporting updated data from KOMET-001 accepted for oral presentation at ASH – – First demonstration of durable clinical response with tipifarnib plus alpelisib in HNSCC – – AIM-HN trial of tipifarnib in HRAS mutant HNSCC closed to further enrollment – – $25 million equity investment from Bristol Myers Squibb and $12 |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 3, 2022 |
EX-10.1 Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 2, 2022, between Kura Oncology, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), and Bristol-Myers Squibb Company, a corporation organized under the laws of the State of Delaware (the “Purchaser”). WHEREAS, subject |
|
| November 3, 2022 |
EX-10.2 Exhibit 10.2 Execution Version LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of November 1, 2022 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, this “Agreement”) and is entered into by and among Kura Oncology, Inc., a Delaware corporation, and each of its Subsidiaries from time to time party hereto (her |
|
| November 3, 2022 |
EX-99.1 Exhibit 99.1 Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million – $25 million equity investment from Bristol Myers Squibb at $18.25 per share – – Term loan facility from Hercules Capital provides up to $125 million – – Proceeds extend Kura’s cash runway into 2026, if term loan is fully drawn – SAN DIEGO, Nov |
|
| November 3, 2022 |
Exhibit 99.1 Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia Harry P. Erba1, Amir Fathi2, Ghayas Issa3, Jessica Altman4, Pau Montesinos5, Mrinal Patnaik6, James Foran7, Stephane DeBotton8, Maria Baer9, Gary Schiller10, Roland Walter11, Marina Kremyanskaya12, Kristin Pettit13, Stephen St |
|
| November 3, 2022 |
1,370,171 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-251172 PROSPECTUS SUPPLEMENT (to Prospectus dated December 7, 2020) 1,370,171 Shares of Common Stock We are offering 1,370,171 shares of our common stock directly to the investor, Bristol-Myers Squibb Company, in this offering at a price per share of $18.2459. This offering is being made without an underwriter or a p |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37620 KURA |
|
| November 3, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 3, 2022 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Kura Oncology, Inc. |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 3, 2022 |
EX-4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPAN |
|
| September 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2022 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37620 KURA ONCOL |
|
| August 3, 2022 |
Exhibit 99.1 Kura Oncology Reports Second Quarter 2022 Financial Results – Recommended Phase 2 dose for ziftomenib identified, pending FDA review – – Additional 18 patients enrolled in KOMET-001 trial of ziftomenib in NPM1-mutant and KMT2A-rearranged AML – – Preliminary activity observed in KURRENT-HN trial of tipifarnib plus alpelisib in PIK3CA-dependent HNSCC, first patient dosed in HRAS overexp |
|
| August 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 23, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2022 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 4, 2022 |
Exhibit 99.1 Kura Oncology Reports First Quarter 2022 Financial Results ? Enrollment completed in Phase 1b expansion cohorts for ziftomenib; topline data expected in third quarter, full data presentation in fourth quarter ? ? Enrollment in PIK3CA-dependent cohort in KURRENT-HN trial of tipifarnib plus alpelisib continues; first patient in HRAS overexpression cohort expected by third quarter ? ? Fi |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q say UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37620 KURA |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| March 10, 2022 |
KURA / Kura Oncology Inc / FMR LLC Passive Investment SCHEDULE 13G Amendment No.12 KURA ONCOLOGY INC COMMON STOCK Cusip #50127T109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #50127T109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 241,209 Item 6: 0 Item 7: 241,463 Item 8: 0 Item 9: 241,463 Item 11: 0.362% It |
|
| February 24, 2022 |
Exhibit 10.31 Kura Oncology, Inc. Executive Employment Agreement for Teresa Bair This Executive Employment Agreement (the ?Agreement?), entered into between Kura Oncology, Inc. (the ?Company?) and Teresa Bair (the ?Executive?) (collectively, the ?Parties?), is effective as of October 18, 2021 (the ?Effective Date?). Whereas, the Company desires Executive to provide employment services to the Compa |
|
| February 24, 2022 |
As filed with the Securities and Exchange Commission on February 24, 2022 As filed with the Securities and Exchange Commission on February 24, 2022 Registration No. |
|
| February 24, 2022 |
$150,000,000 Kura Oncology, Inc. Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-251172 Prospectus Supplement (To Prospectus dated December 7, 2020) $150,000,000 Kura Oncology, Inc. Common Stock We have entered into a sales agreement with SVB Securities LLC, or SVB Securities, Credit Suisse Securities (USA) LLC, or Credit Suisse, and Cantor Fitzgerald & Co., or Cantor, each of whom we refer to as an agent, |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 24, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Kura Oncology, Inc. |
|
| February 24, 2022 |
Exhibit 10.30 Kura Oncology, Inc. RSU Award Grant Notice - International (Amended and Restated 2014 Equity Incentive Plan) Kura Oncology, Inc. (the ?Company?) has awarded to you (the ?Participant?) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the ?RSU Award?). Your RSU Award is subject to all of the terms and conditions as set f |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37620 KURA ONCOLOGY, |
|
| February 24, 2022 |
EX-FILING FEES 4 kura-exfilingfees36.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Kura Oncology, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount |
|
| February 24, 2022 |
Exhibit 10.32 Kura Oncology, Inc. February 4, 2022 Marc Grasso, M.D. Re: Separation Agreement Dear Marc: This letter sets forth the terms of the separation agreement (the ?Agreement?) that Kura Oncology, Inc. (the ?Company?) is offering to you to aid in your employment transition. 1. Resignation. You have informed the Company that you intend to resign from employment with the Company without Good |
|
| February 24, 2022 |
Exhibit 99.1 Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results ? Patient enrollment continues in KOMET-001 Phase 1b study of ziftomenib (KO-539) in AML ? ? Multiple milestones and data readouts from KOMET-001 expected in 2022 ? ? First patients dosed in Phase 1/2 study of tipifarnib plus alpelisib in HNSCC ? ? Abstract supporting next-generation FTI program accepted for pre |
|
| February 24, 2022 |
Exhibit 10.1 EXECUTION VERSION KURA ONCOLOGY, INC. $150,000,000 COMMON STOCK SALES AGREEMENT February 24, 2022 SVB Securities LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, New York 10010 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Kura Oncology, Inc., a Delaware corporatio |
|
| February 11, 2022 |
KURA / Kura Oncology Inc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 11, 2022 |
KURA / Kura Oncology Inc / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 INITIAL FILING KURA ONCOLOGY INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 50127T109 (CUSIP NUMBER) 12/31/2021 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILE |
|
| February 4, 2022 |
KURA / Kura Oncology Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 3, 2022 |
KURA / Kura Oncology Inc / BlackRock Inc. Passive Investment us50127t1097020222.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) Kura Oncology Inc - (Name of Issuer) Common Stock - (Title of Class of Securities) 50127T109 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2022 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| January 31, 2022 |
KURA / Kura Oncology Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Kura Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 50127T109 (CUSIP Number) January 21, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| January 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2022 KURA ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37620 61-1547851 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| January 10, 2022 |
KURA / Kura Oncology Inc / FMR LLC Passive Investment SCHEDULE 13G Amendment No. 11 KURA ONCOLOGY INC COMMON STOCK Cusip #50127T109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #50127T109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 359,389 Item 6: 0 Item 7: 5,582,200 Item 8: 0 Item 9: 5,582,200 Item 11: 8.38 |
